Highlight
The PAX-BD trial investigated pramipexole added to mood stabilisers for treatment-resistant bipolar depression, offering preliminary evidence of improved mood symptoms and psychosocial function without significant primary outcome benefit. The drug was generally well tolerated but associated with increased hypomanic symptoms, mitigated by concurrent antipsychotics. Study limitations included small sample size and COVID-19-related challenges.
